Mason Archival Repository Service

Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection

Show simple item record

dc.contributor.author Benedict, Ashwini
dc.contributor.author Bansal, Neha
dc.contributor.author Senina, Svetlana
dc.contributor.author Hooper, Idris
dc.contributor.author Lundberg, Lindsay
dc.contributor.author de la Fuente, Cynthia
dc.contributor.author Narayanan, Aarthi
dc.contributor.author Gutting, Bradford
dc.contributor.author Kehn-Hall, Kylene
dc.date.accessioned 2016-08-09T00:17:04Z
dc.date.available 2016-08-09T00:17:04Z
dc.date.issued 2015-07-08
dc.identifier.citation Benedict A, Bansal N, Senina S, Hooper I, Lundberg L, de la Fuente C, Narayanan A, Gutting B and Kehn-Hall K (2015) Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection. Front. Microbiol. 6:676. doi: 10.3389/fmicb.2015.00676 en_US
dc.identifier.uri https://hdl.handle.net/1920/10335
dc.description.abstract There are currently no FDA-approved therapeutics available to treat Rift Valley fever virus (RVFV) infection. In an effort to repurpose drugs for RVFV treatment, a library of FDA-approved drugs was screened to determine their ability to inhibit RVFV. Several drugs from varying compound classes, including inhibitors of growth factor receptors, microtubule assembly/disassembly, and DNA synthesis, were found to reduce RVFV replication. The hepatocellular and renal cell carcinoma drug, sorafenib, was the most effective inhibitor, being non-toxic and demonstrating inhibition of RVFV in a cell-type and virus strain independent manner. Mechanism of action studies indicated that sorafenib targets at least two stages in the virus infectious cycle, RNA synthesis and viral egress. Computational modeling studies also support this conclusion. siRNA knockdown of Raf proteins indicated that non-classical targets of sorafenib are likely important for the replication of RVFV.
dc.description.sponsorship Publication of this article was funded in part by the George Mason University Libraries Open Access Publishing Fund. en_US
dc.language.iso en_US en_US
dc.publisher Frontiers en_US
dc.subject Rift valley fever virus en_US
dc.subject Raf en_US
dc.subject Sorafenib en_US
dc.subject Viral egress en_US
dc.subject Replication en_US
dc.subject FDA en_US
dc.title Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection en_US
dc.type Article en_US
dc.identifier.doi http://dx.doi.org/10.3389/fmicb.2015.00676


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search MARS


Browse

My Account

Statistics